167 related articles for article (PubMed ID: 20928937)
21. Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents.
Talati C; Pinilla-Ibarz J
Curr Opin Hematol; 2018 Mar; 25(2):154-161. PubMed ID: 29266016
[TBL] [Abstract][Full Text] [Related]
22. The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
Chen Y; Li D; Li S
Cell Cycle; 2009 Nov; 8(21):3488-92. PubMed ID: 19823023
[TBL] [Abstract][Full Text] [Related]
23. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
24. CD150(-) Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1.
Wang Z; Chen CC; Chen W
Stem Cells; 2015 Dec; 33(12):3437-51. PubMed ID: 26466808
[TBL] [Abstract][Full Text] [Related]
25. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Shah M; Bhatia R
Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
[TBL] [Abstract][Full Text] [Related]
26. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
27. Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia.
Ianniciello A; Helgason GV
Autophagy; 2022 Jul; 18(7):1734-1736. PubMed ID: 35227175
[TBL] [Abstract][Full Text] [Related]
28. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
Chen M; Turhan AG; Ding H; Lin Q; Meng K; Jiang X
Oncotarget; 2017 Jul; 8(27):43662-43677. PubMed ID: 28599273
[TBL] [Abstract][Full Text] [Related]
29. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells.
Zhang H; Peng C; Hu Y; Li H; Sheng Z; Chen Y; Sullivan C; Cerny J; Hutchinson L; Higgins A; Miron P; Zhang X; Brehm MA; Li D; Green MR; Li S
Nat Genet; 2012 Jul; 44(8):861-71. PubMed ID: 22797726
[TBL] [Abstract][Full Text] [Related]
30. The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia.
Wu A; Turner KA; Woolfson A; Jiang X
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986819
[TBL] [Abstract][Full Text] [Related]
31. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
32. Novel combination treatments targeting chronic myeloid leukemia stem cells.
Al Baghdadi T; Abonour R; Boswell HS
Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):94-105. PubMed ID: 22178144
[TBL] [Abstract][Full Text] [Related]
33. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
[TBL] [Abstract][Full Text] [Related]
34. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Danisz K; Blasiak J
Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
[TBL] [Abstract][Full Text] [Related]
35. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
Zhou Z; Liu T; Zhang J
Biochem Biophys Res Commun; 2019 Dec; 520(3):560-565. PubMed ID: 31615652
[TBL] [Abstract][Full Text] [Related]
36. Selective elimination of leukemia stem cells: hitting a moving target.
Crews LA; Jamieson CH
Cancer Lett; 2013 Sep; 338(1):15-22. PubMed ID: 22906415
[TBL] [Abstract][Full Text] [Related]
37. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
[TBL] [Abstract][Full Text] [Related]
38. Leukemia stem cells: the root of chronic myeloid leukemia.
Zhou H; Xu R
Protein Cell; 2015 Jun; 6(6):403-12. PubMed ID: 25749979
[TBL] [Abstract][Full Text] [Related]
39. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
[TBL] [Abstract][Full Text] [Related]
40. Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: key role of stromal microenvironment.
Seke Etet PF; Vecchio L; Nwabo Kamdje AH
Cell Signal; 2012 Sep; 24(9):1883-8. PubMed ID: 22659137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]